RYAN SEVERO: Open Payments
NPI 1952922502 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$727 in 39 payments from 10 companies in 2025. Trend: 2023 $944 · 2024 $814 · 2025 $727
Food & beverage: $727
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $164 |
| Novo Nordisk Inc | 7 | $139 |
| Amgen Inc. | 7 | $114 |
| Exact Sciences Corporation | 3 | $66 |
| Lilly USA, LLC | 3 | $63 |
| PFIZER INC. | 3 | $55 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Insulet Corporation | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
Products named: OTEZLA, Rybelsus, UBRELVY, VRAYLAR, QULIPTA, The Cologuard Plus Collection Kit, TRELEGY ELLIPTA, Ozempic.
Industry payments across FL — which companies pay providers there.
